establish
tg
mous
model
profoundli
sensit
suscept
merscov
infect
determin
high
viral
titer
lung
well
high
rate
morbid
equip
small
anim
model
human
merscov
investig
protect
efficaci
mab
accomplish
group
n
mice
treat
via
intraperiton
ip
rout
two
differ
dose
mg
mg
per
mous
dilut
pb
challeng
intranas
h
post
treatment
ie
merscov
volum
challeng
mice
monitor
daili
clinic
manifest
weight
loss
mortal
shown
fig
group
treat
mg
mab
surviv
viral
infect
without
show
clinic
symptom
mice
initi
show
either
weight
loss
recov
mild
weight
loss
within
three
day
fig
hand
group
treat
mg
mab
show
gradual
weight
loss
day
start
recov
fig
surviv
mice
one
die
day
mice
treat
mg
continu
recov
appear
well
dpi
experi
termin
fig
merscovchalleng
mice
pretreat
high
dose
mg
irrelev
mab
exhibit
profound
weight
loss
succumb
infect
mortal
day
pi
fig
b
determin
therapeut
potenti
human
monoclon
antibodi
group
mice
n
per
group
challeng
merscov
ie
volum
treat
ip
hour
later
singl
dose
either
mg
mg
mg
antibodi
control
per
mous
follow
monitor
daili
wellb
weight
loss
clinic
manifest
mortal
mice
note
wherea
treatment
mg
antibodi
effect
protect
lethal
caus
merscov
infect
fail
protect
mice
fulli
onset
clinic
ill
weight
loss
specif
challeng
mice
treat
mg
antibodi
suffer
attenu
transient
weight
loss
day
gradual
recov
day
experi
termin
fig
similarli
challeng
mice
treat
low
dose
mg
antibodi
suffer
attenu
transient
weight
loss
day
pi
gradual
recov
howev
note
singl
death
day
low
dose
treatment
group
fig
expect
mice
treat
singl
dose
mg
control
antibodi
exhibit
profound
weight
loss
succumb
merscov
infect
mortal
day
pi
fig
taken
togeth
result
indic
merscov
rbdspecif
human
antibodi
highli
effect
prophylact
therapeut
modal
protect
highli
permiss
transgen
mice
merscov
infect
diseas
also
investig
protect
mechan
merscov
determin
lung
viru
titer
challeng
mice
day
treatment
specif
sacrif
two
mice
group
describ
fig
lung
specimen
harvest
determin
viral
titer
use
via
vero
cellbas
infect
assay
quantit
pcr
qpcr
base
assay
target
upstream
e
gene
merscov
shown
fig
unabl
recov
infecti
viru
mous
treat
mg
antibodi
either
challeng
merscov
howev
abl
detect
bare
detect
infecti
viru
limit
detect
lod
log
singl
mous
receiv
mg
prior
viral
challeng
result
indic
mab
like
confer
protect
lethal
challeng
restrict
viral
replic
within
lung
therebi
prevent
viral
infect
brain
organ
titer
viral
rna
copi
number
shown
qrtpcr
assay
also
compar
among
group
differ
dose
mab
lung
infect
mice
harvest
day
post
previru
challeng
group
group
exhibit
detect
viral
rna
titer
significantli
lower
control
group
group
pretreat
group
mice
treat
mg
show
reduct
viral
rna
detect
log
reduct
viral
number
seen
mice
treat
within
mg
compar
mice
receiv
control
mab
posttreat
group
smaller
log
differ
viral
rna
copi
number
compar
pretreat
group
observ
mice
treat
mg
antibodi
compar
receiv
control
antibodi
log
reduct
viral
rna
number
seen
mice
treat
mg
compar
mice
receiv
control
mab
fig
data
indic
confer
signific
protect
mice
administ
pre
postvir
challeng
taken
togeth
result
suggest
us
epitop
target
except
potent
rbdspecif
antibodi
great
potenti
develop
potent
prevent
therapeut
agent
futur
effect
antibodi
treatment
pulmonari
patholog
associ
merscov
infect
evalu
use
formalinfix
paraffin
embed
hematoxylineosin
h
e
stain
lung
specimen
harvest
day
pi
pulmonari
patholog
note
mice
treat
differ
dose
control
antibodi
either
viral
infect
sever
scale
none
mild
moder
sever
h
estain
sampl
mice
pretreat
mg
mg
antibodi
grade
respect
perivascular
intraalveolar
infiltr
mononuclear
cell
includ
lymphocyt
macrophagesmonocyt
fig
middl
panel
wherea
obtain
mice
receiv
postinfect
treatment
either
dose
grade
fig
right
panel
compar
grade
assign
mice
receiv
control
antibodi
treatment
prior
infect
fig
left
panel
merscov
attract
signific
basic
research
clinic
studi
sinc
first
discov
earli
even
though
transmiss
merscov
among
human
remain
low
present
mutationpron
rna
viru
could
eventu
evolv
highli
communic
virul
human
pathogen
emphas
urgent
need
develop
effect
antivir
therapi
could
restrict
spread
deadli
diseas
viral
infect
neutral
antibodi
shown
protect
host
diseas
progress
andor
reduc
sever
clinic
symptom
passiv
immunotherapi
prophylaxi
treatment
infecti
viral
diseas
wide
use
mani
passiv
transfer
neutral
antibodi
also
promis
strategi
prophylaxi
treatment
merscov
infect
end
other
success
demonstr
protect
efficaci
specif
human
neutral
monoclon
antibodi
anim
model
merscov
among
panel
merscovspecif
mab
gener
use
vast
phage
display
identifi
three
mab
specif
bind
merscov
rbd
high
affin
among
three
identifi
note
mab
exhibit
highest
potenc
neutral
live
merscov
character
novel
human
mab
tg
mous
model
merscov
infect
show
prophylact
therapeut
protect
mice
treat
lethal
challeng
viru
respect
thu
mab
highli
promis
potent
inhibitor
urgent
prophylaxi
adjunct
treatment
patient
infect
merscov
studi
note
passiv
transfer
mg
mg
monoclon
antibodi
individu
mice
h
prior
challeng
merscov
result
protect
lethal
respect
fig
suggest
use
mg
prophylaxi
suboptim
complet
neutral
viral
infect
therebi
allow
residu
virus
replic
within
lung
cours
infect
data
demonstr
confer
dosedepend
reduct
merscov
infect
corrobor
lower
viral
rna
level
live
viru
isol
determin
mice
compar
control
mice
studi
also
confirm
therapeut
efficaci
dosedepend
manner
similar
prophylact
studi
administr
singledos
antibodi
concentr
either
mg
per
mous
h
merscov
challeng
provid
protect
respect
infectioninduc
lethal
accompani
reduc
viral
load
infecti
viru
viral
rna
within
lung
howev
also
note
recoveri
bodyweight
loss
reduct
viral
load
mice
treat
mg
hr
infect
slower
treat
mg
shown
fig
respect
clear
evid
show
advers
impact
overal
wellb
mice
impos
upon
treatment
mg
antibodi
merscov
challeng
fig
difficult
complet
rule
exist
subtl
yettob
investig
highdos
drug
toxic
specul
subtl
highdos
drug
toxic
phase
acut
dynam
merscov
infect
initi
hr
treatment
mg
could
exacerb
drug
toxic
result
reduct
appetit
antivir
capac
howev
neg
impact
impos
upon
highdos
treatment
viral
infect
mice
appear
transient
irrevers
alter
final
outcom
infect
judg
mortal
fig
addit
studi
especi
pharmacokinet
dose
frequenc
warrant
futur
optim
prevent
therapeut
strategi
promis
antibodi
transgen
mice
use
evalu
prophylact
especi
therapeut
efficaci
antibodi
extrem
sensit
merscov
infect
diseas
merscov
respect
data
shown
titer
lower
origin
strike
abil
antibodi
prophylact
therapeut
agent
significantli
protect
transgen
mice
challeng
merscov
highli
impress
rbd
merscov
target
antibodi
highli
conserv
among
variou
clinic
isol
mutat
rate
rbd
appear
extrem
low
compar
rna
therebi
make
develop
escap
mutant
unlik
howev
combin
treatment
multipl
neutral
mab
target
differ
epitop
merscovspecif
fusion
inhibitor
target
domain
subunit
merscov
could
desir
immun
mice
rbd
merscov
protein
li
et
al
recent
develop
human
mab
name
exhibit
strong
neutral
activ
pseudotyp
live
merscov
less
potent
pseudotyp
live
merscov
respect
use
mous
demonstr
intraven
administr
singl
dose
one
day
merscov
challeng
result
reduct
viral
titer
log
dpi
howev
intraperiton
administr
tg
mice
lead
reduct
viral
titer
high
log
dpi
sinc
merscov
challeng
mice
show
sever
diseas
effect
weight
loss
mortal
mice
unavail
addit
unlik
transgen
mice
use
studi
welldefin
express
well
lethal
dose
infecti
dose
intens
express
among
mice
variabl
rang
undetect
high
although
bind
rbd
merscov
protein
critic
amino
acid
residu
recogn
two
mab
epitop
overlap
extens
site
compos
merscov
rbd
residu
epitop
mab
parent
mous
mab
overlap
partial
site
compos
five
rbd
residu
rbd
amino
acid
recogn
includ
locat
site
indic
neutral
efficaci
larg
attribut
steric
hindranc
creat
bind
merscov
result
suggest
combin
use
may
exhibit
synergist
antivir
effect
wildtyp
strain
escap
mutant
merscov
taken
togeth
result
suggest
us
merscov
rbd
proteinspecif
mab
excel
candid
passiv
immunotherapi
provid
immedi
effect
protect
individu
may
expos
merscov
treat
patient
expos
test
human
need
potenti
use
therapeut
treatment
merscovinfect
patient
express
previous
describ
use
infect
cell
atcc
manassa
va
polyfect
transfect
reagent
qiagen
valencia
ca
screen
clone
antibodi
product
elisa
subsequ
character
stabl
cell
line
gener
inocul
bioflo
bioreactor
new
brunswick
scientif
nj
largescal
product
purif
carri
use
protein
g
column
ge
healthcar
endotoxin
remov
detoxigel
endotoxin
remov
column
thermo
scientif
accord
manufactur
instruct
transgen
mice
express
human
establish
us
use
throughout
studi
anim
hous
onsit
anim
facil
galveston
nation
laboratori
lightdark
cycl
room
temperatur
humid
kept
respect
ad
libitum
access
food
water
experi
perform
accord
guid
nih
aaalac
approv
institut
anim
care
use
committe
univers
texa
medic
branch
describ
briefli
group
tg
mice
challeng
intranas
origin
provid
heinz
feldmann
nih
niaid
rocki
mountain
laboratori
hamilton
mt
ron
fouchier
erasmu
medic
center
rotterdam
netherland
titer
individu
viru
stock
store
determin
use
vero
infect
assay
express
tissu
cultur
infecti
dose
ml
anim
studi
involv
infecti
merscov
conduct
within
approv
anim
biosafeti
level
galveston
nation
laboratori
experiment
design
strategi
differ
tg
mous
group
involv
intranas
challeng
live
merscov
describ
individu
experi
result
section
live
viru
isol
lung
tissu
collect
day
post
merscov
challeng
weigh
homogen
phosphatebuff
salin
pb
contain
fetal
calf
serum
fc
use
tissuelys
qiagen
retsch
haan
germani
previous
result
suspens
infect
tissu
titter
standard
vero
cellbas
infect
assay
quantifi
yield
infecti
viru
express
per
gram
g
tissu
lung
tissu
sampl
group
mice
transfer
individu
vial
rna
later
solut
qiagen
subsequ
homogen
subject
total
rna
isol
use
trizol
reagent
life
technolog
assess
merscovspecif
genom
target
virusspecif
upstream
e
gene
upe
endogen
control
gene
mous
use
onestep
rtpcr
kit
invitrogen
previous
ct
valu
sampl
analyz
ct
valu
gener
lab
standard
curv
merscov
mrna
copi
number
rel
merscov
upe
mrna
express
valu
calcul
replic
express
equival
per
gram
g
tissu
standard
threshold
cycl
method
ct
valu
analysi
done
use
biorad
cfx
manag
softwar
mice
necropsi
lung
tissu
inflat
fix
neutral
buffer
formalin
day
paraffinembed
process
routin
hematoxylin
eosin
stain
h
e
assess
cite
articl
agraw
et
al
passiv
transfer
germlinelik
neutral
human
monoclon
antibodi
protect
transgen
mice
lethal
middl
east
respiratori
syndrom
coronaviru
infect
sci
rep
doi
